D-1133-2018 Class II Terminated

Recalled by AVKARE Inc. — Pulaski, TN

FDA drug recall D-1133-2018 was initiated by AVKARE Inc. on Aug 14, 2018 and is designated Class II. Reason for recall: CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. The recall status is terminated (terminated May 7, 2020). Affected quantity: 1496 cartons (44,880 tablets).

Recall Details

Product Type
Drugs
Report Date
Sep 5, 2018
Initiation Date
Aug 14, 2018
Termination Date
May 7, 2020
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
1496 cartons (44,880 tablets)

Product Description

Valsartan Tablets, USP 320 mg Rx Only 30 Tablets (6x5) Unit Dose NDC 50268-786-13 Manufactured for: AvKARE, Inc. Pulaski, TN 38478

Reason for Recall

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Distribution Pattern

U.S. Nationwide

Code Information

Lots: 17718 Exp. 07/2018; 18700 Exp. 01/2019; 19133 Exp. 02/2019; 19532 Exp. 04/2019

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1133-2018
openFDA file date
Oct 23, 2026
Loaded by RegDataLab
Oct 24, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.